Many thanks to Chloe Kent at In Vivo for her great interview with our CEO Young Kwon. In her story, titled Alchemab Is Bringing A New Meaning To Patient Centered Care, Chloe explores how the first step in our drug discovery journey starts with individual patients. As we target diseases across neurology and oncology through […]

Alchemab was delighted to be featured in Nature Biotechnology in a profile by Michael Eisenstein. In the article he speaks with Young Kwon, our CEO, and Jane Osbourn, our founder and CSO, about Alchemab’s revolutionary approach of looking for protective antibodies in ‘resilient’ people which may provide a new approach for discovering drug targets: “Our […]